Clinical Trials Logo

Alzheimer's Disease clinical trials

View clinical trials related to Alzheimer's Disease.

Filter by:

NCT ID: NCT00927108 Withdrawn - Multiple Sclerosis Clinical Trials

Rajavtihi Neuronal Adult Stem Cells Project

RNASc
Start date: July 2009
Phase: Phase 2
Study type: Interventional

To study the success of Oligodendrocyte progenitor cell culture project in Rajavithi Hospital to identify an unlimited clone human neuronal progenitor stem cells from the human brain in the Biomolecular Research Center. This study aims to produce the reproductive clone of neuronal development protocols and advance projects. Neuronal cells such as pyramidal cells, oligodendrocyte, and dopaminergic neuron differentiation protocol/projects for treatment of Alzheimer's disease, Multiple sclerosis, and Parkinson's disease respectively in next phase of clinical trials.

NCT ID: NCT00884533 Withdrawn - Alzheimer's Disease Clinical Trials

QTc Study of Rosi XR in Healthy Volunteers

Rosi XR
Start date: June 2009
Phase: Phase 1
Study type: Interventional

This study is a randomised double blind, parallel group, and will evaluate the effects of repeat oral doses of RSG- XR for 21 days on the QTc interval compared to placebo in a population of healthy adult males and females.

NCT ID: NCT00792662 Withdrawn - Diabetes Mellitus Clinical Trials

Improving Function, Quality of Life, Glycemia in Diabetics With Dementia

Start date: November 18, 2008
Phase: Phase 4
Study type: Interventional

The primary purpose of this study is to determine if the study medication Methylphenidate (Ritalin) will improve subject's blood-sugar control by improving their motivation more than placebo. The secondary objectives of the study are to determine if daily functioning and quality of life improves with methylphenidate treatment.

NCT ID: NCT00691340 Withdrawn - Alzheimer's Disease Clinical Trials

Cellular Proteome From Leukocytes of Glaucoma Patients in Comparison With Patients With Alzheimer's Disease

Start date: June 2008
Phase: N/A
Study type: Observational

Glaucoma is a worldwide leading cause of blindness. The key feature of this ocular neuropathy is characterized by an excavating optic nerve head. Loss of retinal ganglion cells is the final end point in blinding diseases of the optic nerve such as glaucoma. It is known that neuronal cell death in glaucoma occurs by an apoptotic mechanism. In earlier studies the investigators could demonstrate that the process of apoptosis is reflected in circulating leukocytes by different parameters, like differential mRNA expression and an increased fragmentation of the DNA. Such alterations point out a relationship between cellular stress and apoptotic events. Based on the results of mRNA-expression the investigators also expect alterations on the protein level. This study is, therefore, designed to characterize the proteome related to the proteins involved in cell death related pathways. Thus, the expression pattern of several proteins in leukocytes from patients with primary open angle glaucoma will be analyzed by techniques like Western-blot and tandem mass spectrometry. These samples will be compared with samples from healthy controls. In addition, they will also be compared with samples from patients with Alzheimer's disease. Since glaucoma is a neurodegenerative disease, these patients will be included as positive controls in this study.

NCT ID: NCT00412048 Withdrawn - Alzheimer's Disease Clinical Trials

Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease

Start date: April 2012
Phase: N/A
Study type: Interventional

The aim of the protocol is to study the resting brain activation profile of 3 groups of people, using a new fMRI procedure, called fMRI-SAM. fMRI-SAM will be applied to 25 Alzheimer's disease (AD) patients, 25 patients suffering from amnestic - mild cognitive impairment (MCI) - a clinical picture which may be a prodromal form of AD - and 60 healthy controls. The first analysis of the data will search differences of brain activation profiles between the 3 groups. In the second step, the investigators will study the predictive value of fMRI-SAM to detect MCI patients who will later convert to AD.

NCT ID: NCT00375557 Withdrawn - Dementia Clinical Trials

Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients

Start date: October 2006
Phase: Phase 4
Study type: Interventional

The primary aim is to determine whether Divalproex ER or one of the atypical antipsychotics is more effective improving dementia related behavioral symptoms in patients with dementia, and evaluate the impact of such improvements on other clinical domains, such as quality of life, functional status.